NCT04020575: Phase I Study of Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

NCT04020575
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MUC1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Restrictions on the number of lines of previous treatment- see trial for details
Exclusions: Patients with untreated unstable CNS metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT04020575

Comments are closed.

Up ↑